Sphingolipids and Diagnosis, Prognosis, and Organ Damage in Systemic Lupus Erythematosus
| العنوان: | Sphingolipids and Diagnosis, Prognosis, and Organ Damage in Systemic Lupus Erythematosus |
|---|---|
| المؤلفون: | Olivia C Harden, Samar M. Hammad |
| المصدر: | Frontiers in Immunology Frontiers in Immunology, Vol 11 (2020) |
| بيانات النشر: | Frontiers Media SA, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | lcsh:Immunologic diseases. Allergy, 0301 basic medicine, medicine.medical_specialty, End organ damage, Immunology, Review, Disease, sphingomyelin, sphingolipidomics, 03 medical and health sciences, 0302 clinical medicine, immune system diseases, Internal medicine, medicine, Animals, Humans, Lupus Erythematosus, Systemic, Immunology and Allergy, ceramide, skin and connective tissue diseases, sphingosine 1-phosphate, Cause of death, Autoimmune disease, Sphingolipids, Systemic lupus erythematosus, sphingosine, business.industry, lupus, Prognosis, medicine.disease, Sphingolipid, Clinical trial, Organ damage, 030104 developmental biology, lipidomics, sphingolipid, lcsh:RC581-607, business, Biomarkers, 030215 immunology |
| الوصف: | Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that involves multiple organs and disproportionality affects females, especially African Americans from 15 to 44 years of age. SLE can lead to end organ damage including kidneys, lungs, cardiovascular and neuropsychiatric systems, with cardiovascular complications being the primary cause of death. Usually, SLE is diagnosed and its activity is assessed using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Systemic Lupus International Collaborating Clinics Damage Index (SLICC/ACR), and British Isles Lupus Assessment Group (BILAG) Scales, which unfortunately often occurs after a certain degree of systemic involvements, disease activity or organ damage already exists. There is certainly a need for the identification of early biomarkers to diagnose and assess disease activity as well as to evaluate disease prognosis and response to treatment earlier in the course of the disease. Here we review advancements made in the area of sphingolipidomics as a diagnostic/prognostic tool for SLE and its co-morbidities. We also discuss recent reports on differential sphingolipid metabolism and blood sphingolipid profiles in SLE-prone animal models as well as in diverse cohorts of SLE patients. In addition, we address targeting sphingolipids and their metabolism as a method of treating SLE and some of its complications. Although such treatments have already shown promise in preventing organ-specific pathology caused by SLE, further investigational studies and clinical trials are warranted. |
| تدمد: | 1664-3224 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6bc573e94d29aaed2a2b6ac2b489468Test https://doi.org/10.3389/fimmu.2020.586737Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....f6bc573e94d29aaed2a2b6ac2b489468 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16643224 |
|---|